
BEIGF
Healthcare · Biotechnology · $32.59B market cap
$21.950.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 5, 2026 | After the close | — | 0.16 | — |
| May 6, 2026 | After the close | — | 0.15 | — |
| Feb 26, 2026 | After the close | — | 0.04 | — |
| Nov 6, 2025 | After the close | — | 0.08 | — |
| Aug 6, 2025 | After the close | — | 0.06 | — |
| May 6, 2025 | Before the open | — | 0.00 | — |
| Feb 24, 2025 | Before the open | — | -0.11 | — |
| Nov 12, 2024 | Before the open | — | -0.09 | — |
| Aug 7, 2024 | Before the open | — | -0.09 | — |
| May 8, 2024 | Before the open | — | -0.19 | — |
| Feb 26, 2024 | Before the open | — | -0.27 | — |
| Feb 27, 2023 | Before the open | -0.57 | -0.33 | +42.1% |
| May 5, 2022 | Before the open | -1.68 | -0.33 | +80.4% |
| Aug 5, 2021 |
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various…
| After the close |
| — |
| -0.40 |
| — |
| May 6, 2021 | After the close | — | 0.05 | — |
| Nov 5, 2020 | After the close | -4.06 | -0.37 | +90.9% |
| Aug 6, 2020 | After the close | — | -0.33 | — |
| May 11, 2020 | After the close | -0.34 | -0.36 | -5.9% |
| Feb 26, 2020 | After the close | -0.39 | -0.49 | -25.6% |
| Nov 12, 2019 | After the close | -0.37 | -0.39 | -5.4% |
| Aug 8, 2019 | After the close | — | -0.11 | — |